Peapod Lane Capital LLC Buys Shares of 507,868 Ikena Oncology, Inc. (NASDAQ:IKNA)

Peapod Lane Capital LLC purchased a new stake in shares of Ikena Oncology, Inc. (NASDAQ:IKNA) in the fourth quarter, HoldingsChannel.com reports. The fund purchased 507,868 shares of the company’s stock, valued at approximately $833,000.

Several other institutional investors have also modified their holdings of the company. AQR Capital Management LLC purchased a new position in Ikena Oncology in the 2nd quarter valued at approximately $36,000. BML Capital Management LLC grew its holdings in Ikena Oncology by 23.6% in the third quarter. BML Capital Management LLC now owns 723,288 shares of the company’s stock valued at $1,251,000 after purchasing an additional 138,174 shares during the last quarter. FMR LLC increased its position in shares of Ikena Oncology by 94.1% in the third quarter. FMR LLC now owns 38,374 shares of the company’s stock valued at $66,000 after buying an additional 18,607 shares in the last quarter. BBR Partners LLC increased its position in shares of Ikena Oncology by 550.0% in the third quarter. BBR Partners LLC now owns 130,000 shares of the company’s stock valued at $225,000 after buying an additional 110,000 shares in the last quarter. Finally, NEA Management Company LLC raised its stake in shares of Ikena Oncology by 5.3% during the 3rd quarter. NEA Management Company LLC now owns 600,063 shares of the company’s stock worth $1,038,000 after buying an additional 30,013 shares during the last quarter. Hedge funds and other institutional investors own 75.00% of the company’s stock.

Analyst Ratings Changes

IKNA has been the topic of a number of research reports. HC Wainwright reissued a “buy” rating and issued a $4.00 price objective on shares of Ikena Oncology in a research note on Monday, November 11th. Wedbush reiterated a “neutral” rating and issued a $2.00 price target on shares of Ikena Oncology in a research report on Monday, December 23rd.

Ikena Oncology Price Performance

Ikena Oncology stock opened at $1.46 on Thursday. Ikena Oncology, Inc. has a fifty-two week low of $1.22 and a fifty-two week high of $1.94. The stock has a fifty day moving average of $1.56 and a two-hundred day moving average of $1.65.

About Ikena Oncology

Ikena Oncology, Inc operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.